Abstract
PURPOSE: To describe changes in intraocular pressure (IOP) in the 'alternative treatments to Inhibit VEGF in Age-related choroidal Neovascularisation (IVAN)' trial (registered as ISRCTN92166560).
DESIGN: Randomised controlled clinical trial with factorial design.
PARTICIPANTS: Patients (n=610) with treatment naïve neovascular age-related macular degeneration were enrolled and randomly assigned to receive either ranibizumab or bevacizumab and to two regimens, namely monthly (continuous) or as needed (discontinuous) treatment.
METHODS: At monthly visits, IOP was measured preinjection in both eyes, and postinjection in the study eye.
OUTCOME MEASURES: The effects of 10 prespecified covariates on preinjection IOP, change in IOP (postinjection minus preinjection) and the difference in preinjection IOP between the two eyes were examined.
RESULTS: For every month in trial, there was a statistically significant rise in both the preinjection IOP and the change in IOP postinjection during the time in the trial (estimate 0.02 mm Hg, 95% CI 0.01 to 0.03, p<0.001 and 0.03 mm Hg, 95% CI 0.01 to 0.04, p=0.002, respectively). There was also a small but significant increase during the time in trial in the difference in IOP between the two eyes (estimate 0.01 mm Hg, 95% CI 0.005 to 0.02, p<0.001). There were no differences between bevacizumab and ranibizumab for any of the three outcomes (p=0.93, p=0.22 and p=0.87, respectively).
CONCLUSIONS: Anti-vascular endothelial growth factor agents induce increases in IOP of small and uncertain clinical significance.
TRIAL REGISTRATION NUMBER: ISRCTN92166560.
| Original language | English |
|---|---|
| Pages (from-to) | 1662-1667 |
| Number of pages | 6 |
| Journal | British Journal of Ophthalmology |
| Volume | 100 |
| Issue number | 12 |
| Early online date | 12 Apr 2016 |
| DOIs | |
| Publication status | Published - 1 Dec 2016 |
Research Groups and Themes
- BTC (Bristol Trials Centre)
- Centre for Surgical Research